Your Current Position: NEWS > Industry Trends
-
On Mar.18, 2019, Cold Genesys, an American company developing a form of cancer immunotherapy using genetically engineered viruses, has closed a $22 million round of funding.
-
【Industry Trends】 Sep. 13, 2018 Boehringer Ingelheim buyed an oncolytic virus R&D company called ViraTherapeutics in $244M deal2018-09-14On Sep. 13, 2018, the German company Boehringer Ingelheim (BI) announced the acquisition of Vira Therapeutics, an oncolytic virus research and development company based in Austria.
-
【Industry Trends】 J Clin Invest 128(4): The mechanism of tumor resistance to oncolytic viruses discovered2018-06-07An article entitled "PD-L1 in tumor microenvironment mediates resistance to oncolytic immunotherapy" published online in the J Clin Invest indicates that PD-L1
-
2018-05-15In Nature, a news titled “Cancer killing viruses show promise – and draw billion-dollar investment” mentioned, pharmaceutical giant Johnson & Johnson announced on 2
-
On Feb. 22, 2018, Merck and Viralytics announced acquisition agreement and the proposed acquisition values the total issued shares in Viralytics at approximately AUD 502 million (USD 394 million).
-
【Industry Trends】 Science Translational Medicine 10 (422): Oncolytic virus immunotherapy breakthrough again2018-02-01In the 10th issue of the 422th issue of Science Translational Medicine, the new results of oncolyticvirus-related immunotherapy were on the cover in the journal Science Translational Medicine 10(422).
-
【Industry Trends】 Sep. 7, 2017 Cell: Oncolytic virus and c-Rel inhibitors make immunotherapy more effective2018-01-11Immunotherapy is a promising approach in the treatment of cancer; but for most patients, immunotherapy drugs so far have failed to live up to their promise and provide little or no benefit. Immunotherapy